NEW YORK (GenomeWeb News) – Protein biomarker company Peakadilly today said it has raised €8.5 million ($10.9 million) in the second and final round of its series A financing.
 
Peakadilly said it will use the cash to increase the capacity of its protein biomarker-discovery operation, which is based on its MASStermind technology.
 
It will also enable it to “accelerate development of its own diagnostic and pharmacodiagnostic products,” the firm said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.